BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,633,454 | -16.9% | 126,832 | -0.3% | 0.20% | -11.8% |
| Q2 2023 | $10,384,316 | +16.5% | 127,212 | +5.9% | 0.22% | +16.3% |
| Q1 2023 | $8,914,225 | -12.6% | 120,154 | -2.3% | 0.19% | -17.4% |
| Q4 2022 | $10,195,566 | +15.0% | 123,016 | +294.0% | 0.23% | +1.3% |
| Q3 2022 | $8,867,000 | -19.9% | 31,222 | -2.2% | 0.23% | -24.3% |
| Q2 2022 | $11,071,000 | +9.6% | 31,937 | +36.9% | 0.30% | +16.7% |
| Q1 2022 | $10,104,000 | -18.6% | 23,333 | -2.8% | 0.26% | -14.3% |
| Q4 2021 | $12,414,000 | -15.9% | 23,995 | -21.2% | 0.30% | -23.3% |
| Q3 2021 | $14,764,000 | +3.4% | 30,469 | -3.9% | 0.39% | -2.0% |
| Q2 2021 | $14,281,000 | -22.2% | 31,718 | -34.0% | 0.40% | -24.3% |
| Q1 2021 | $18,349,000 | +10.9% | 48,043 | -7.8% | 0.53% | -2.8% |
| Q4 2020 | $16,544,000 | +27.3% | 52,100 | -0.7% | 0.54% | -2.7% |
| Q3 2020 | $12,999,000 | +7.2% | 52,471 | +14.2% | 0.56% | +1.5% |
| Q2 2020 | $12,131,000 | +38.7% | 45,937 | -0.4% | 0.55% | +10.2% |
| Q1 2020 | $8,745,000 | +14.4% | 46,117 | +32.4% | 0.50% | +65.4% |
| Q4 2019 | $7,647,000 | +46.4% | 34,836 | +30.5% | 0.30% | +31.4% |
| Q3 2019 | $5,223,000 | -6.4% | 26,692 | -0.3% | 0.23% | -8.4% |
| Q2 2019 | $5,579,000 | +2.9% | 26,760 | -2.0% | 0.25% | -2.3% |
| Q1 2019 | $5,423,000 | +22.9% | 27,311 | -10.4% | 0.26% | +7.1% |
| Q4 2018 | $4,411,000 | -21.1% | 30,482 | +11.2% | 0.24% | -4.0% |
| Q3 2018 | $5,594,000 | +16.6% | 27,406 | -15.5% | 0.25% | +9.7% |
| Q2 2018 | $4,798,000 | +5.0% | 32,432 | +7.2% | 0.23% | +0.4% |
| Q1 2018 | $4,568,000 | +63.8% | 30,243 | +40.5% | 0.23% | +62.6% |
| Q4 2017 | $2,788,000 | +13.9% | 21,521 | +6.3% | 0.14% | +13.9% |
| Q3 2017 | $2,448,000 | -11.3% | 20,247 | -13.8% | 0.12% | -16.4% |
| Q2 2017 | $2,759,000 | +22.1% | 23,484 | +5.6% | 0.15% | +22.7% |
| Q1 2017 | $2,260,000 | +76.6% | 22,232 | +78.5% | 0.12% | +52.6% |
| Q4 2016 | $1,280,000 | -10.9% | 12,452 | -5.1% | 0.08% | -13.3% |
| Q3 2016 | $1,436,000 | -28.6% | 13,117 | -26.4% | 0.09% | -31.3% |
| Q2 2016 | $2,011,000 | +3.9% | 17,832 | -12.9% | 0.13% | 0.0% |
| Q1 2016 | $1,935,000 | +47.6% | 20,475 | +40.5% | 0.13% | +45.6% |
| Q4 2015 | $1,311,000 | -2.7% | 14,571 | 0.0% | 0.09% | +3.4% |
| Q3 2015 | $1,347,000 | -59.8% | 14,571 | -57.2% | 0.09% | -53.7% |
| Q2 2015 | $3,349,000 | -29.9% | 34,008 | -28.6% | 0.19% | -22.6% |
| Q1 2015 | $4,778,000 | +6.5% | 47,640 | -1.9% | 0.24% | +3.0% |
| Q4 2014 | $4,487,000 | -14.4% | 48,565 | -13.3% | 0.24% | -19.5% |
| Q3 2014 | $5,243,000 | – | 56,045 | – | 0.29% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |